0001708138-20-000044.txt : 20200420 0001708138-20-000044.hdr.sgml : 20200420 20200420192900 ACCESSION NUMBER: 0001708138-20-000044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200416 FILED AS OF DATE: 20200420 DATE AS OF CHANGE: 20200420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Landry Robert E CENTRAL INDEX KEY: 0001585160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20803683 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-04-16 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001585160 Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP Finance CFO Common Stock 2020-04-16 4 M 0 4000 272.7 A 28373 D Common Stock 2020-04-16 4 F 0 3009 529.79 D 25364 D Common Stock 2020-04-17 4 S 0 33 540.7 D 25331 D Common Stock 2020-04-17 4 S 0 33 542.25 D 25298 D Common Stock 2020-04-17 4 S 0 61 548.99 D 25237 D Common Stock 2020-04-17 4 S 0 3 550.0 D 25234 D Common Stock 2020-04-17 4 S 0 55 551.38 D 25179 D Common Stock 2020-04-17 4 S 0 62 553.85 D 25117 D Common Stock 2020-04-17 4 S 0 33 556.43 D 25084 D Common Stock 2020-04-17 4 S 0 89 558.63 D 24995 D Common Stock 2020-04-17 4 S 0 155 559.25 D 24840 D Common Stock 2020-04-17 4 S 0 232 560.31 D 24608 D Common Stock 2020-04-17 4 S 0 92 561.96 D 24516 D Common Stock 2020-04-17 4 S 0 33 562.77 D 24483 D Common Stock 2020-04-17 4 S 0 66 563.63 D 24417 D Common Stock 2020-04-17 4 S 0 44 565.77 D 24373 D Common Stock 2020-04-17 4 M 0 12500 272.7 A 36873 D Common Stock 2020-04-17 4 F 0 9250 555.82 D 27623 D Common Stock 2020-04-20 4 S 0 35 562.71 D 27588 D Common Stock 2020-04-20 4 S 0 225 563.74 D 27363 D Common Stock 2020-04-20 4 S 0 340 564.76 D 27023 D Common Stock 2020-04-20 4 S 0 902 565.52 D 26121 D Common Stock 2020-04-20 4 S 0 944 566.44 D 25177 D Common Stock 2020-04-20 4 S 0 114 567.76 D 25063 D Common Stock 2020-04-20 4 S 0 126 568.11 D 24937 D Common Stock 2020-04-20 4 S 0 66 569.22 D 24871 D Common Stock 2020-04-20 4 S 0 114 571.65 D 24757 D Common Stock 2020-04-20 4 S 0 64 572.42 D 24693 D Common Stock 2020-04-20 4 S 0 320 573.4 D 24373 D Common Stock 200 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 272.7 2020-04-16 4 M 0 4000 0.0 D 2023-09-09 Common Stock 4000 31500 D Non-Qualified Stock Option (right to buy) 272.7 2020-04-17 4 M 0 12500 0.0 D 2023-09-09 Common Stock 12500 19000 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 89 shares of Company stock on April 17, 2020 at prices ranging from $558.61 to $558.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Represents volume-weighted average price of sales of 155 shares of Company stock on April 17, 2020 at prices ranging from $559.21 to $559.39. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Represents volume-weighted average price of sales of 232 shares of Company stock on April 17, 2020 at prices ranging from $560.02 to $560.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Represents volume-weighted average price of sales of 92 shares of Company stock on April 17, 2020 at prices ranging from $561.92 to $561.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Represents volume-weighted average price of sales of 66 shares of Company stock on April 17, 2020 at prices ranging from $563.39 to $563.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Represents volume-weighted average price of sales of 225 shares of Company stock on April 20, 2020 at prices ranging from $563.56 to $563.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 340 shares of Company stock on April 20, 2020 at prices ranging from $564.14 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 902 shares of Company stock on April 20, 2020 at prices ranging from $565.05 to $565.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 944 shares of Company stock on April 20, 2020 at prices ranging from $566.01 to $566.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 126 shares of Company stock on April 20, 2020 at prices ranging from $568.10 to $568.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 66 shares of Company stock on April 20, 2020 at prices ranging from $569.10 to $569.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 64 shares of Company stock on April 20, 2020 at prices ranging from $572.19 to $572.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 320 shares of Company stock on April 20, 2020 at prices ranging from $573.01 to $573.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. The stock option award vests in four equal annual installments, commencing one year after the date of grant. /s/**Robert E. Landry 2020-04-20